News & Updates
Filter by Specialty:
Vedolizumab lowers risk of severe CDI in patients with ulcerative colitis
Treatment with vedolizumab is associated with a reduced adjusted risk of severe Clostridioides difficile infection (CDI), but not total CDI, in patients with ulcerative colitis (UC), reports a study. Additionally, cytomegalovirus colitis (CMVC) is not seen in those who initiated vedolizumab.
Vedolizumab lowers risk of severe CDI in patients with ulcerative colitis
25 Jul 2023
Rotavirus infection linked to gastroenteritis, neurological complications in children
Children with rotavirus infection are at risk of developing gastroenteritis with severe but self-limiting neurological manifestations, reveals a study.
Rotavirus infection linked to gastroenteritis, neurological complications in children
20 Jul 2023
Phase III data support long-term efficacy of TAF against HBV
Two phase III studies presented at EASL 2023 reflected the long-term efficacy of tenofovir alafenamide (TAF) for individuals with HBeAg*-positive and HBeAg-negative chronic hepatitis B virus (HBV).
Phase III data support long-term efficacy of TAF against HBV
18 Jul 2023
‘Triple-G’ obesity drug also targets NAFLD in phase II trial
In a subanalysis of a phase II trial on obesity, retatrutide, a triagonist of GIP*, GLP**, and glucagon receptors, also demonstrated multiple favourable signals for nonalcoholic fatty liver disease (NAFLD).
